ADC Therapeutics (ADCT) Gains from Investment Securities (2023 - 2026)
ADC Therapeutics' (ADCT) quarterly Gains from Investment Securities came in at -$2.2 million in Q1 2026, down 460.96% year-on-year from $616970.7 in Q1 2025, and down 571.82% quarter-over-quarter from $472000.0 in Q4 2025.
ADC Therapeutics (ADCT) Gains from Investment Securities (2023 - 2026) Analysis & Trends
ADC Therapeutics has disclosed Gains from Investment Securities across 4 years of filings, most recently posting -$2.2 million for Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at -$2.2 million, down 460.96% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.2 million (down 262.52% YoY), and the FY2025 annual result was $46000.0, down 93.12% from the prior year.
- Gains from Investment Securities came in at -$2.2 million for Q1 2026 at ADC Therapeutics, down from $472000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $2.2 million in Q2 2024 to a low of -$2.2 million in Q1 2026.
- The 4-year median for Gains from Investment Securities is -$20000.0 (2023), against an average of -$39909.1.
- Peak annual rise in Gains from Investment Securities reached 11100.0% in 2024, while the deepest fall reached 707.14% in 2024.
- ADC Therapeutics' Gains from Investment Securities stood at $279000.0 in 2023, then surged by 139.78% to $669000.0 in 2024, then retreated by 29.45% to $472000.0 in 2025, then sank by 571.82% to -$2.2 million in 2026.
- The last three Gains from Investment Securities figures came in at -$2.2 million (Q1 2026), $472000.0 (Q4 2025), and -$426000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | ADC Therapeutics | 167.24 Mn | -63.76 Mn | 7.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.23 Mn |
| Mar 31, 2026 | -2.23 Mn |
| Dec 31, 2025 | 472,000.00 |
| Dec 31, 2025 | 472,000.00 |
| Sep 30, 2025 | -426,000.00 |
| Sep 30, 2025 | -426,000.00 |
| Mar 31, 2025 | -397,000.00 |
| Mar 31, 2025 | -397,000.00 |
| Dec 31, 2024 | 669,000.00 |
| Dec 31, 2024 | 669,000.00 |
| Sep 30, 2024 | -1.13 Mn |
| Sep 30, 2024 | -1.13 Mn |
| Jun 30, 2024 | 2.20 Mn |
| Jun 30, 2024 | 2.20 Mn |
| Mar 31, 2024 | 281,000.00 |
| Mar 31, 2024 | 281,000.00 |
| Dec 31, 2023 | 279,000.00 |
| Dec 31, 2023 | 279,000.00 |
| Sep 30, 2023 | -140,000.00 |
| Sep 30, 2023 | -140,000.00 |